Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 13/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18675244 | 0.88 | PSMB9 (0.35) | OPRM1OPRK1DPP4PSMB9HDAC8 | |
| SCHEMBL17282583 | 0.86 | OPRM1 (0.44) | OPRM1OPRK1CNR2DPP4PSMB9 | |
| SCHEMBL25496865 | 0.86 | HDAC8 (0.45) | OPRM1OPRK1CNR2HDAC8 | |
| SCHEMBL22280077 | 0.86 | HDAC8 (0.45) | OPRM1OPRK1CNR2HDAC8 | |
| SCHEMBL25494519 | 0.79 | OPRM1 (0.42) | OPRM1OPRK1CNR2DPP4PIK3CA | |
| SCHEMBL3601920 | 0.78 | HDAC8 (0.47) | OPRM1OPRK1HDAC8 | |
| SCHEMBL18681135 | 0.77 | PREP (0.38) | DPP4PIK3CA | |
| SCHEMBL18681117 | 0.76 | PIN1 (0.52) | CNR2DPP4PSMB9PIK3CA | |
| SCHEMBL18681072 | 0.75 | PREP (0.45) | PIK3CA | |
| SCHEMBL5203085 | 0.74 | HDAC8 (0.51) | OPRM1OPRK1CNR2DPP4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | OPRM1 2215/4885OPRK1 1467/4885CNR2 4786/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | OPRM1 2610/4885OPRK1 1956/4885CNR2 4813/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | OPRM1 2610/4885OPRK1 1956/4885CNR2 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.